Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy

Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the study.

2. Males and non-pregnant, non-nursing females between 18 and 65 years of age

3. Rotator cuff tendinopathy (unilateral) with positive "Painful Arc Test" onexamination

4. Symptoms present for at least 6 weeks but not more than 6 months at Baseline

5. Moderate to severe rotator cuff tendinopathy demonstrated by all of the followingcriteria:

6. WORC score ≤ 40 at Baseline

7. NRS pain score ≥ 5 at Baseline and at least 3 days of the past 7 days prior toBaseline

8. Nocturnal pain at least 4 out of past 7 days in the week prior to Baseline

9. Failure to at least 8 weeks of conventional therapy prior to Baseline: inadequateresponse to NSAIDs and/or paracetamol and physiotherapy; or intolerance to NSAIDsand/or paracetamol

Exclusion Criteria:

1. Greater than 50% partial thickness tear as established by MRI or ultrasound duringassessment in Run-in phase

2. Patients who are expected to require glucocorticoid treatment throughout the trialduration at Baseline (e.g., systemic, intramuscular, local injections in shoulder)

3. Previous surgery, or plans for surgery, during the study period, in the affectedshoulder

4. Rheumatologic and chronic inflammatory diseases, including but not limited toinflammatory bowel disease, polymyalgia rheumatica (PMR), PsA, axSpA and rheumatoidarthritis (RA), fibromyalgia or severe pain disorder unrelated to the targetshoulder

5. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodiespositive at Screening

6. History of adhesive capsulitis/frozen shoulder or calcification in the tendon (inaffected or contralateral shoulder) confirmed clinically or by medical imaging

7. Symptomatic osteoarthritis of the shoulder (glenohumeral, acromioclavicular) inaffected or contralateral shoulder confirmed by medical imaging

8. Patients with traumatic rupture that would be considered eligible for surgery forrepair of cuff tear.

9. Neurological conditions including but not limited to cervical radiculopathy, whichin the opinion of the investigator may explain the patient's symptoms

10. Any intra-articular/subacromial glucocorticoid treatment within 12 weeks prior toBaseline or more than 2 injections for the current tendinopathy.

11. Any oral, intramuscular or i.v. glucocorticoid treatment 12 weeks prior to Baselineor during the current tendinopathy, whichever takes longer

12. Previous platelet rich plasma (PRP) injections or fluoroquinolone/quinoloneantibiotics within 12 weeks prior to Baseline or during the current tendinopathy,whichever takes longer

13. Neuromuscular or primary/secondary muscular deficiency which limits the ability toperform functional measurement (e.g., shoulder strength test)

14. Previous hyaluronic injections within 12 weeks prior to Baseline or during thecurrent tendinopathy, whichever takes longer